2023 Q3 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Third Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.

2023 Q2 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Second Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.

Deal Makers of Japan, Volume 3

The Deal Makers of Japan series aims to bridge the gap and offer insight to a global biopharma audience to the Japanese pharma industry. We are pleased to present the third volume of the Deal Makers of Japan - Exclusive Interviews with Japan’s best dealmakers,...

2023 Q1 Report: Global Trends in Biopharma Transactions

Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2023 Frist Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.

RNA Therapeutics Landscape Overview

Locust Walk views RNA therapeutics in 5 key pillars: RNA Translation Inhibition, Protein Expression, RNA-Targeting Small Molecules, RNA Editing, and RNA-Mediated Protein and Transcriptome Regulation.